Findings of Research Misconduct, 124-125 [2011-33650]
Download as PDF
<![CDATA[
124
Federal Register / Vol. 77, No. 1 / Tuesday, January 3, 2012 / Notices
indicate that the settlement is
inappropriate, improper, or inadequate.
The Agency’s response to any comments
received will be available for public
inspection at the City of Los Angeles
Central Library, Science and
Technology Department, 630 West 5th
Street, Los Angeles CA 90071 and at the
EPA Region 9 Superfund Records
Center, Mail Stop SFD–7C, 95
Hawthorne Street, Room 403, San
Francisco, CA 94105.
DATES: Comments must be submitted on
or before February 2, 2012.
ADDRESSES: The proposed settlement is
available for public inspection at the
EPA Region 9 Superfund Records
Center, Mail Stop SFD–7C, 95
Hawthorne Street, Room 403, San
Francisco, CA 94105. A copy of the
proposed settlement may also be
obtained from the EPA Region 9
Superfund Record Center, 95
Hawthorne Street, Mail Stop SFD–7C,
Room 403, San Francisco, CA 94105,
(415) 820–4700. Comments should
reference the North Hollywood
Operable Unit of the San Fernando
Valley Area 1 Superfund Site, and EPA
Docket No. 9–2011–0015 and should be
addressed to Michael Massey, EPA
Region 9, 75 Hawthorne Street, Mail
Stop ORC–3, San Francisco, CA 94105.
FOR FURTHER INFORMATION CONTACT:
Kelly Manheimer, EPA Region 9, 75
Hawthorne Street, Mail Stop SFD–7–1,
San Francisco, CA 94105, (415) 972–
3290.
Dated: December 22, 2011.
Kathleen Salyer,
Acting Superfund Division Director.
[FR Doc. 2011–33667 Filed 12–30–11; 8:45 am]
BILLING CODE 6560–50–P
ENVIRONMENTAL PROTECTION
AGENCY
[FRL–9612–9]
Biological Processors of Alabama;
Decatur, Morgan County, AL; Notice of
Settlement
Environmental Protection
Agency.
ACTION: Notice of Settlement.
AGENCY:
Under Section 122(h)(1) of the
Comprehensive Environmental
Response, Compensation and Liability
Act (CERCLA), the United States
Environmental Protection Agency has
entered into a settlement for
reimbursement of past response costs
concerning the Biological Processors of
Alabama Superfund Site located in
Decatur, Morgan County, Alabama.
pmangrum on DSK3VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:13 Dec 30, 2011
Jkt 226001
The Agency will consider public
comments on the settlement until
February 2, 2012. The Agency will
consider all comments received and
may modify or withdraw its consent to
the settlement if comments received
disclose facts or considerations which
indicate that the settlement is
inappropriate, improper, or inadequate.
ADDRESSES: Copies of the settlement are
available from Ms. Paula V. Painter.
Submit your comments by Site name
Biological Processors of Alabama
Superfund Site by one of the following
methods:
• www.epa.gov/region4/waste/sf/
enforce.htm.
• Email. Painter.Paula@epa.gov.
FOR FURTHER INFORMATION CONTACT:
Paula V. Painter at (404) 562–8887.
DATES:
Dated: December 14, 2011.
Anita L. Davis,
Chief, Superfund Enforcement & Information
Management Branch, Superfund Division.
[FR Doc. 2011–33680 Filed 12–30–11; 8:45 am]
BILLING CODE 6560–50–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Jennifer Jamieson, State University of
New York, Upstate Medical University:
Based on the report of an investigation
conducted by the State University of
New York, Upstate Medical University
(SUNY US) and additional analysis
conducted by ORI in its oversight
review, ORI found that Ms. Jennifer
Jamieson, former graduate student,
Department of Cell and Developmental
Biology, SUNY US, engaged in research
misconduct in research supported by
National Institute of General Medical
Sciences (NIGMS), National Institutes of
Health (NIH), grant R01 GM047607–
18A1, and National Heart, Lung, and
Blood Institute (NHLBI), NIH, grants
R01 HL70244–05.
ORI found that Respondent engaged
in research misconduct by falsifying
data that were included in grant
application R01 GM047607–18A1, in a
manuscript submitted for publication to
the Journal of Cell Biology, and in
several interdepartmental data
presentations. Specifically, ORI found
that:
SUMMARY:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
• Respondent falsified Figure 1A in a
manuscript submitted for publication to
the Journal of Cell Biology, by altering
immunoprecipitation Western blot data
to make this experiment appear that no
Vav2 SH2 was associated with PKL 3YF,
when in fact it did. In addition, the
Respondent falsified five figures
depicting Western blots of similar
experiments in four laboratory meeting
presentations. The purpose of the
falsifications was to show that the
experimental results were as described
when they were not, or to show that the
results were of greater significance than
they actually were.
• Respondent falsified Figure 3I in a
manuscript submitted for publication to
the Journal of Cell Biology by falsely
labeling a Western blot to indicate levels
of expression for various Vav2 mutants,
when the experimental data were taken
from a completely unrelated
experiment.
• Respondent falsified Figure 6A in
an interdepartmental laboratory
presentation by falsifying Western blot
data to falsely depict Paxillin and Hic5 expression and phosphorylation levels
after siRNA treatment.
• Respondent falsified Figure 5 from
NIGMS, NIH, grant application
GM047607–18A1, by falsifying Western
blot data to support the hypothesis that
co-transfection of PKL plus RhoA GEF
Vav2 induces RhoA activation and
signaling upon plating on fibronectin.
Ms. Jamieson has entered into a
Voluntary Settlement Agreement
(Agreement). Ms Jamieson neither
admits nor denies ORI’s finding of
scientific misconduct nor any particular
finding of fact asserted in support of
that finding. The settlement is not an
admission of liability on the part of the
Respondent.
Ms. Jamieson has voluntarily agreed
for a period of three (3) years, beginning
on December 20, 2011:
(1) To have her research supervised if
employed by an institution that receives
or applies for U.S. Public Health Service
(PHS) funding; Respondent agrees that
prior to the submission of an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of her duties is
submitted to ORI for approval; the
supervision plan must be designed to
ensure the scientific integrity of
Respondent’s research contribution;
Respondent agrees that she shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
E:\FR\FM\03JAN1.SGM
03JAN1
Federal Register / Vol. 77, No. 1 / Tuesday, January 3, 2012 / Notices
Respondent agrees to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) that any institution employing her
shall submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHS
supported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology were
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude herself from serving in
any advisory capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2011–33650 Filed 12–30–11; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Mahesh Visvanathan, Ph.D., Kansas
University: Based on an inquiry
conducted and written admission
obtained by Kansas University (KU) and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Mahesh Visvanathan, Research
Assistant Professor in the K–INBRE 1
Bioinformatics Core Facility, KU,
engaged in research misconduct in
research supported by U.S. Public
Health Service (PHS) funds, specifically
the INBRE program of the National
Center for Research Resources (NCRR),
National Institutes of Health (NIH),
grant P20 RR016475.
Specifically, ORI found that
Respondent engaged in research
pmangrum on DSK3VPTVN1PROD with NOTICES
SUMMARY:
1 K–INBRE: The Kansas IDeA Network of
Biomedical Research Excellence, which is a
consortium of a number of schools and centers in
Kansas.
VerDate Mar<15>2010
15:13 Dec 30, 2011
Jkt 226001
misconduct by intentionally and
knowingly plagiarizing large amounts of
text from other writers’ published
papers without attribution or citation in
the following three (3) papers and one
(1) abstract. The specific published
documents as well as the relevant
source documents are:
• Visvanathan, M., Adagarla, B.,
Lushington, G., Sittampalam, S.,
Proceedings of the 2009 International
Joint Conference on Bioinformatics,
Systems, Biology and Intelligent
Computing, 2009, 494–497. Greater than
half (50%) of the total text was obtained
from (1) Yang, C.–S., Chuang, L.–Y., Ke,
C.–H., Yang, C.–H., International
Journal of Computer Science,
International Association of Engineers,
August 2008 35(3), (2) Goffard, N. and
Weiller, G., Nucleic Acids Research,
2007, 35L:W176– W18l, and (3) Chuang,
L.–Y., Yang, C.–H., Tu, C.–J., Yang, C.–
H., Proceedings of the Joint Conference
on Information Sciences, Atlantis Press,
October 2006.
Retracted: Retracted administratively
by IEEE on Jan 5, 2011 https://
ieeexplore.ieee.org/xpl/
freeabs_all.jsp?arnumber=5260432.
• Vijayan, A.; Skariah, B. E., Nair, B.;
Lushington, G., Subramanian, S.,
Visvanathan, M., Proceedings of the
IEEE International Conference on
Bioinformatics and Biomedicine
Workshop, 2009, BIBMW2009, 267–271.
Approximately 15%of the text was
plagiarized from Goffard, N. and
Weiller, G., Nucleic Acids Research,
2007, 35L:W176–W18l.
Retracted: Retracted administratively
by IEEE on Jan 5, 2011 https://
www.computer.org/portal/web/csdl/doi/
10.1109/BIBMW.2009.5332106.
• Visvanathan, M., Netzer, M., Seger,
M., Adagarla, B. S., Baumgartner, C.,
Sittampalam, S., Lushington, G.,
International Journal of Computational
Biology and Drug Design, 2009, 2,236–
251. A complete paragraph of the text
was plagiarized from Goffard, N. and
Weiller, G., Nucleic Acids Research,
2007, 35L:W176– W18l.
• Adagarla, B., Lushington, G.,
Visvanathan, M., ISMB International
Conference, January 2009; the entire
abstract for this poster was obtained by
plagiarizing text from Pihur, V., Datta,
S., Datta S., Genomics, 2003, 92:400–
403.
Dr. Visvanathan has entered into a
Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed
for a period of two (2) years, beginning
on December 20, 2011:
(1) To have any PHS-supported
research supervised; ORI acknowledges
that Respondent’s research is currently
being supervised by KU; Respondent
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
125
shall ensure that a plan for supervision
of his PHS-related duties is submitted to
ORI for approval either within two
weeks of this Agreement becoming final
or prior to receiving or applying for PHS
funds if such support is not current at
the time this Agreement is completed;
the supervision plan must be designed
to ensure the scientific integrity of his
research contribution; because of the
ongoing review of Respondent’s
research by KU, ORI will only require a
summary report on the first and second
anniversary of the Agreement detailing
how KU has ensured that Respondent’s
research and language in PHS grant
applications and reports of PHSsupported research have been verified to
be his own and accurately reported;
Respondent agrees to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) That this annual summary,
provided by any institution employing
him, shall provide assurance that each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent was involved, was based on
actual experiments or was otherwise
legitimately derived, that the data,
procedures, and methodology were
accurately reported in the application,
report, manuscript, or abstract, and that
the text in such submissions was his
own or properly cited the source of
copied language and ideas; and
(3) To exclude himself from serving in
any advisory capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852. (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2011–33651 Filed 12–30–11; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–D–0916]
Draft Guidance for Industry and Food
and Drug Administration Staff; Medical
Device Classification Product Codes;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
E:\FR\FM\03JAN1.SGM
Notice.
03JAN1
]]>Agencies
[Federal Register Volume 77, Number 1 (Tuesday, January 3, 2012)]
[Notices]
[Pages 124-125]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-33650]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Jennifer Jamieson, State University of New York, Upstate Medical
University: Based on the report of an investigation conducted by the
State University of New York, Upstate Medical University (SUNY US) and
additional analysis conducted by ORI in its oversight review, ORI found
that Ms. Jennifer Jamieson, former graduate student, Department of Cell
and Developmental Biology, SUNY US, engaged in research misconduct in
research supported by National Institute of General Medical Sciences
(NIGMS), National Institutes of Health (NIH), grant R01 GM047607-18A1,
and National Heart, Lung, and Blood Institute (NHLBI), NIH, grants R01
HL70244-05.
ORI found that Respondent engaged in research misconduct by
falsifying data that were included in grant application R01 GM047607-
18A1, in a manuscript submitted for publication to the Journal of Cell
Biology, and in several interdepartmental data presentations.
Specifically, ORI found that:
Respondent falsified Figure 1A in a manuscript submitted
for publication to the Journal of Cell Biology, by altering
immunoprecipitation Western blot data to make this experiment appear
that no Vav2 SH2 was associated with PKL 3YF, when in fact it did. In
addition, the Respondent falsified five figures depicting Western blots
of similar experiments in four laboratory meeting presentations. The
purpose of the falsifications was to show that the experimental results
were as described when they were not, or to show that the results were
of greater significance than they actually were.
Respondent falsified Figure 3I in a manuscript submitted
for publication to the Journal of Cell Biology by falsely labeling a
Western blot to indicate levels of expression for various Vav2 mutants,
when the experimental data were taken from a completely unrelated
experiment.
Respondent falsified Figure 6A in an interdepartmental
laboratory presentation by falsifying Western blot data to falsely
depict Paxillin and Hic-5 expression and phosphorylation levels after
siRNA treatment.
Respondent falsified Figure 5 from NIGMS, NIH, grant
application GM047607-18A1, by falsifying Western blot data to support
the hypothesis that co-transfection of PKL plus RhoA GEF Vav2 induces
RhoA activation and signaling upon plating on fibronectin.
Ms. Jamieson has entered into a Voluntary Settlement Agreement
(Agreement). Ms Jamieson neither admits nor denies ORI's finding of
scientific misconduct nor any particular finding of fact asserted in
support of that finding. The settlement is not an admission of
liability on the part of the Respondent.
Ms. Jamieson has voluntarily agreed for a period of three (3)
years, beginning on December 20, 2011:
(1) To have her research supervised if employed by an institution
that receives or applies for U.S. Public Health Service (PHS) funding;
Respondent agrees that prior to the submission of an application for
PHS support for a research project on which the Respondent's
participation is proposed and prior to Respondent's participation in
any capacity on PHS-supported research, Respondent shall ensure that a
plan for supervision of her duties is submitted to ORI for approval;
the supervision plan must be designed to ensure the scientific
integrity of Respondent's research contribution; Respondent agrees that
she shall not participate in any PHS-supported research until such a
supervision plan is submitted to and approved by ORI;
[[Page 125]]
Respondent agrees to maintain responsibility for compliance with the
agreed upon supervision plan;
(2) that any institution employing her shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology were accurately reported in the
application, report, manuscript, or abstract; and
(3) to exclude herself from serving in any advisory capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
John Dahlberg,
Director, Division of Investigative Oversight, Office of Research
Integrity.
[FR Doc. 2011-33650 Filed 12-30-11; 8:45 am]
BILLING CODE 4150-31-P
